PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score

This is a prospective study that will assess the impact of MammaPrint on chemotherapy + endocrine versus endocrine alone treatment decisions in patients with an Oncotype Intermediate Score.

Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.

Investigator(s):

Intervention(s):

  • device : MammaPrint

Phase: N/A

Eligibility

Ages Eligible For Study:

18 Years - 90 Years

Inclusion Criteria

- Women with histologically proven invasive stage I-II, node negative, hormone receptor positive, Her2 negative breast cancer, who received an Oncotype DX intermediate score (18-30) - ? 18 years of age at time of consent - Written informed consent

External Links

Explore related trials

Contact information

Primary Contact:

Annabel Castaneda 650-498-7977

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: